10x Genomics Earnings Call Transcripts
Fiscal Year 2026
-
Double-digit growth in consumables and strong cash flow were achieved despite macro headwinds. Product innovation, especially Flex Apex and Xenium, is driving new customer adoption and volume growth. Biopharma and large-scale projects are key future growth drivers, while competitive intensity has eased.
-
Revenue exceeded guidance with strong growth in both instruments and consumables, driven by late-quarter CapEx and robust demand for Flex and spatial assays. Strategic partnerships and product innovation are fueling expansion into translational research, AI-driven projects, and clinical diagnostics, despite ongoing capital market challenges.
Fiscal Year 2025
-
Q4 2025 revenue exceeded guidance despite a challenging funding environment, with strong growth in consumables—especially from FLEX APEX and Xenium—while instrument sales declined. 2026 guidance anticipates flat to modest revenue growth, continued cost discipline, and double-digit consumables growth, with ongoing CapEx constraints and robust cash reserves.
-
Major restructuring and commercial changes have positioned the organization to navigate a challenging market, with strong product innovation and improved competitive standing. Ongoing pricing strategies and new launches are driving volume growth, while AI and large-scale data initiatives present significant future opportunities.
-
Q3 2025 revenue reached $149M, exceeding guidance despite macro headwinds. Spatial consumables, especially Xenium, drove double-digit growth, while single-cell volumes rose but faced pricing pressure. Q4 revenue is guided up 5% sequentially, with continued investment in innovation.
-
Restructuring and product innovation have positioned the business for growth despite macro headwinds. Academic and biopharma markets remain cautious, but strong product launches and strategic acquisitions are driving optimism. Single cell and spatial platforms continue to gain traction, with large-scale studies underscoring future potential.
-
Q2 revenue reached $173M, boosted by a $68M Bruker settlement; excluding this, revenue declined year-over-year. Consumables and spatial platforms showed growth, but instrument sales and academic funding remain pressured. The Scale Biosciences acquisition aims to enhance single cell capabilities.
-
Macroeconomic uncertainty and policy changes have pressured U.S. academic funding, but strong growth in consumables and new product adoption, especially in China and with the Xenium platform, support cautious optimism. Product innovation and organizational changes position the business for long-term growth in both academic and biopharma markets.
-
Q1 revenue declined 2% year-over-year (excluding settlement), with strong consumables growth offsetting weak instrument sales. Uncertainty in U.S. research funding led to withdrawal of annual guidance, replaced by quarterly outlook. Cost-saving actions and new product launches support long-term growth.
-
Major product launches and commercial restructuring in 2024 have positioned the business for growth despite macroeconomic and NIH funding challenges. Double-digit growth is expected in spatial platforms, with pharma and translational research driving future expansion. Free cash flow positivity is anticipated for 2025.
-
Management highlighted strong 2024 results, driven by major product launches and operational scaling. New lower-cost, high-performance tools are expanding market reach, especially in biopharma and translational research. Ongoing commercial reorganization and innovation position the company for long-term growth.
Fiscal Year 2024
-
2024 revenue declined 1% to $610.8M amid macro and funding headwinds, but new product launches and a sales force reorganization set the stage for future growth. 2025 guidance projects flat to modest growth, with double-digit gains in spatial and Chromium volumes, while NIH funding uncertainty remains a key risk.
-
2024 has been challenging due to macroeconomic pressures and internal transitions, but optimism is high as new products and commercial restructuring position the business for growth. NIH funding remains stable, China exposure is limited, and customer feedback on recent launches is strong.
-
Q3 revenue declined 1% year-over-year due to sales restructuring and macro headwinds, with full-year guidance lowered to a 3% decline from 2023. Consumables grew, especially in spatial, but instrument sales fell sharply. Commercial reorganization and new product launches are expected to drive future growth.
-
Major product launches across all platforms and strong customer feedback have driven momentum, despite macroeconomic headwinds affecting instrument sales. Leadership changes and a sales force reorganization aim to boost efficiency and growth, with a focus on expanding accessibility and lowering costs over time.
-
Q2 revenue rose 4% YoY to $153.1M, led by strong spatial consumables growth, but instrument sales declined due to macro headwinds. 2024 revenue guidance was lowered to $640–$660M, reflecting ongoing CapEx constraints and commercial restructuring. Free cash flow was positive in Q2.